<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02903160</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 16-1593</org_study_id>
    <secondary_id>CABAZL07459</secondary_id>
    <secondary_id>ONC-2014-168</secondary_id>
    <nct_id>NCT02903160</nct_id>
  </id_info>
  <brief_title>Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)</brief_title>
  <official_title>Clinical Trial of a Rapidly Cycling, Non-Cross Reactive Regimen of Approved Therapeutic Agents to Treat Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the clinical benefits of using a rapidly cycling,&#xD;
      non-cross reactive regimen of FDA-approved prostate cancer therapeutic agents in the&#xD;
      management of castration resistant prostate cancer. The hypothesis is that the identification&#xD;
      of optimal combinations and sequencing of therapies can help prevent or delay the development&#xD;
      of therapeutic drug resistance, and can be safely tolerated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase II clinical trial will explore the efficacy of rapidly cycling non-cross reactive&#xD;
      treatment therapies in the treatment of patients with newly diagnosed mCRPC. The primary&#xD;
      hypothesis is that the best chance of eliminating or controlling disease is when the cancer&#xD;
      is treatment naïve, and has not yet developed therapeutic resistance. By finding an optimal&#xD;
      drug deployment strategy of already approved and available treatments for mCRPC, the&#xD;
      researchers believe providers can more effectively treat an intrinsically heterogeneous&#xD;
      disease, delay/prevent drug resistance, as well as minimize treatment toxicity.&#xD;
&#xD;
      All of the treatment agents selected have well-defined individual toxicity profiles from&#xD;
      large phase III trials, but there is limited clinical data about the toxicity profiles of&#xD;
      these drugs in combinations. While each agent is generally well tolerated, toxicities remain&#xD;
      a significant concern given the older age of the typical mCRPC patient, the comorbid&#xD;
      conditions common to this patient population, as well as those borne from previous chronic&#xD;
      androgen deprivation therapy.&#xD;
&#xD;
      Each drug in the proposed treatment regimen will be used at their FDA-approved dosing and&#xD;
      indication, with the exception of cabazitaxel, which will be used prior to disease&#xD;
      demonstration of docetaxel failure, and in combination with carboplatin. The proposed&#xD;
      sequencing is rationally designed, and based on each drug's distinct mechanisms of action as&#xD;
      well as their toxicity profiles.&#xD;
&#xD;
      The rapidly-cycling treatment regimen contains three, separate, consecutive treatment&#xD;
      modules, each lasting 3 months: 1. Abiraterone; 2. Cabazitaxel + Carboplatin; 3. Enzalutamide&#xD;
      + Radium-223. Therapeutic agents are delivered as non-cross reactive combinations, in order&#xD;
      to achieve optimal therapeutic dosing at each cycle and decrease possibility of significant&#xD;
      adverse effects.&#xD;
&#xD;
      To the researcher knowledge, no study has evaluated the use of rapidly cycling, non-cross&#xD;
      reactive therapies for the treatment of mCRPC. The hypothesis is that the identification of&#xD;
      optimal combinations and sequencing of rapidly cycling non-cross reactive therapies can help&#xD;
      prevent or delay the development of therapeutic drug resistance, and can be safely tolerated.&#xD;
&#xD;
      Primary objective is to evaluate the time to disease progression after completion of all&#xD;
      modules of the rapidly-cycling, non-cross reactive regimen in patients with mCRPC. Secondary&#xD;
      objectives are to evaluate overall survival, prostate-specific antigen (PSA) response rate&#xD;
      with each treatment module, changes to alkaline phosphatase level, and assess safety of the&#xD;
      rapidly-cycling, non-cross reactive regimen. Additional exploratory objective are to evaluate&#xD;
      the correlation of a peripheral whole-blood RNA signature with clinical outcome measures&#xD;
      during and after treatment, and to evaluate changes to AR-V7 expression in CTCs with&#xD;
      different treatment modalities and clinical outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 13, 2017</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to disease progression</measure>
    <time_frame>average 24 months</time_frame>
    <description>Time to disease progression, as determined by either PSA or radiographic progression, after completion of all modules of the rapidly-cycling, non-cross reactive regimen in patients with mCRPC.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA response rate</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes to alkaline phosphatase levels</measure>
    <time_frame>baseline and 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Intensive, Non-Cross Reactive Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prostate Cancer Rapidly cycling, Intensive, Non-Cross Reactive Therapy (PRINT) Rapidly cycling, consecutive treatment modules: 1. Abiraterone acetate; 2. Cabazitaxel + Carboplatin; 3. Enzalutamide + Radium-223</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone acetate</intervention_name>
    <description>Abiraterone acetate 1000 mg PO daily</description>
    <arm_group_label>Intensive, Non-Cross Reactive Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>5 mg PO twice a day</description>
    <arm_group_label>Intensive, Non-Cross Reactive Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radium-223 dichloride</intervention_name>
    <description>50 kBq/kg IV monthly</description>
    <arm_group_label>Intensive, Non-Cross Reactive Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cabazitaxel</intervention_name>
    <description>25 mg/m2 IV every 3 weeks</description>
    <arm_group_label>Intensive, Non-Cross Reactive Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin AUC 4 IV every 3 weeks</description>
    <arm_group_label>Intensive, Non-Cross Reactive Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide</intervention_name>
    <description>160 mg PO daily</description>
    <arm_group_label>Intensive, Non-Cross Reactive Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
          -  Metastatic castrate resistant prostate cancer, defined by progressive disease based on&#xD;
             either rising PSA, new bone metastases, or progression of measurable disease on&#xD;
             standard imaging, according to PCWG2 guidelines, despite androgen deprivation therapy&#xD;
&#xD;
          -  Ongoing androgen deprivation therapy with a GnRH analogue, GnRH antagonist, or&#xD;
             bilateral orchiectomy&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Serum testosterone level &lt; 50 ng/dL&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,500/μL, platelet count &gt; 100,000/μL, and hemoglobin &gt; 9&#xD;
             g/dL&#xD;
&#xD;
          -  Creatinine &lt; 2 mg/dL&#xD;
&#xD;
          -  Total bilirubin &lt; 1 times the upper limit of normal, alanine aminotransferase (ALT) or&#xD;
             aspartate aminotransferase (AST) ≤ 1.5 times the upper limit of normal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of uncontrolled seizure disorder&#xD;
&#xD;
          -  Clinically significant cardiovascular disease including:&#xD;
&#xD;
               1. Myocardial infarction or uncontrolled angina within 6 months&#xD;
&#xD;
               2. Congestive heart failure New York Heart Association (NYHA) class 3 or 4, or&#xD;
                  patients with history of congestive heart failure NYHA class 3 or 4 in the past&#xD;
&#xD;
               3. Uncontrolled hypertension as indicated by a resting systolic blood pressure &gt; 170&#xD;
                  mmHg or diastolic blood pressure &gt; 105 mmHg at the screening visit&#xD;
&#xD;
          -  Have used or plan to use from 30 days prior to enrollment through the end of the study&#xD;
             medication known to lower the seizure threshold or prolong the QT interval&#xD;
&#xD;
          -  Major surgery within 4 weeks of enrollment&#xD;
&#xD;
          -  Radiation therapy within 4 weeks of enrollment&#xD;
&#xD;
          -  Prior use of abiraterone acetate, enzalutamide, docetaxel, cabazitaxel, carboplatin,&#xD;
             or radium-223 for the treatment of castration-resistant disease&#xD;
&#xD;
          -  Prior docetaxel use in the hormone-sensitive disease setting is allowed, but must be&#xD;
             completed ≥ 4 weeks prior to enrollment&#xD;
&#xD;
          -  Prior sipuleucel-T use is allowed, but must be completed ≥ 4 weeks prior to enrollment&#xD;
&#xD;
          -  Concurrent use of zoledronic acid or denosumab is allowed on study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bobby Liaw, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bobby Liaw, MD</last_name>
    <phone>212-604-6010</phone>
    <email>bobby.liaw@mountsinai.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mount Sinai Beth Israel</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bobby Liaw, MD</last_name>
      <phone>212-604-6010</phone>
      <email>bobby.liaw@mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>Bobby Liaw, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai West</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Oh, MD</last_name>
      <phone>212-659-5549</phone>
      <email>william.oh@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>William Oh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 7, 2016</study_first_submitted>
  <study_first_submitted_qc>September 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2016</study_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Bobby Liaw</investigator_full_name>
    <investigator_title>Assistant Profesor</investigator_title>
  </responsible_party>
  <keyword>Castration resistant</keyword>
  <keyword>Prostate cancer</keyword>
  <keyword>Metastatic</keyword>
  <keyword>First-line</keyword>
  <keyword>Treatment naive</keyword>
  <keyword>Rapidly cycling</keyword>
  <keyword>Non-cross resistant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
    <mesh_term>Radium Ra 223 dichloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

